These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2101497)

  • 1. [Urothelial tumor markers: update].
    de Castro F; Rosell D; Agüera LG; Isa W; Sánchez de la Muela P; Robles JE; Zudaire JJ; Berián JM
    Rev Med Univ Navarra; 1990; 34(3):167-71. PubMed ID: 2101497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a new bladder tumor marker.
    Grossman HB; Liebert M; Sakakibara N; Wedemeyer GA; Stein JA; Washington RW
    Urol Clin North Am; 1991 Aug; 18(3):509-13. PubMed ID: 1877113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ancillary methods for the detection of recurrent urothelial neoplasia.
    Ross JS; Cohen MB
    Cancer; 2000 Apr; 90(2):75-86. PubMed ID: 10794156
    [No Abstract]   [Full Text] [Related]  

  • 4. [The use of monoclonal antibodies in the evaluation of the aggressiveness of tumors of the bladder].
    Ravery V; Popov Z; Bellot J; Abbou CC; Chopin DK
    Ann Urol (Paris); 1993; 27(1):45-50. PubMed ID: 8470880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New diagnostic tests for urothelial tumors of the bladder].
    Irani J
    Prog Urol; 1998 Sep; 8(4):481-6. PubMed ID: 9834508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macroscopic, microscopic and molecular observations of bladder cancer.
    Rowland RG
    J Urol; 2001 May; 165(5):1480. PubMed ID: 11342900
    [No Abstract]   [Full Text] [Related]  

  • 7. [Behavior of the ABO(H) blood group antigens of the urothelial surface in bladder tumors].
    Proca E; Lucan M; Pîslăraşu M
    Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1987; 36(6):401-12. PubMed ID: 2964680
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer.
    Bonner RB; Liebert M; Hurst RE; Grossman HB; Bane BL; Hemstreet GP
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):971-8. PubMed ID: 8959319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary tumor marker for urothelial cancer].
    Ohtani M; Iwasaki A; Shiraiwa H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers and prognostic parameters in urinary bladder cancer].
    Schneider AW; Huland H
    Urologe A; 1990 Mar; 29(2):71-6. PubMed ID: 2184571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.
    Black PC; Brown GA; Dinney CP
    J Clin Oncol; 2006 Dec; 24(35):5528-35. PubMed ID: 17158538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder.
    Kajiwara H; Yasuda M; Kumaki N; Shibayama T; Osamura Y
    Tokai J Exp Clin Med; 2005 Sep; 30(3):177-82. PubMed ID: 16285609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunolabelling of urothelial bladder tumors. Value of 2 monoclonal antibodies and perspective in cytology].
    Pluot M; Bahroum K; Joundi A; Ducrot P; Diebold MD
    Arch Anat Cytol Pathol; 1988; 36(3):69-74. PubMed ID: 2462408
    [No Abstract]   [Full Text] [Related]  

  • 15. Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma.
    Loy TS; Alexander CJ; Calaluce RD
    Mod Pathol; 1995 Aug; 8(6):587-90. PubMed ID: 8532688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple cell markers and flow cytometry in invasive bladder cancer.
    Javadpour N
    Prog Clin Biol Res; 1988; 260():189-201. PubMed ID: 3283759
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer].
    Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ
    Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of detection.
    Messing E
    Urol Oncol; 2007; 25(4):344-7. PubMed ID: 17628306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
    Gregersen B; Mommsen S; Svanholm H
    Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.